Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy
Open Access
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (5) , 685-691
- https://doi.org/10.1023/a:1011115107615
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancerBritish Journal of Cancer, 1996
- Primary medical (neo-adjuvant) chemotherapy for operable breast cancerEuropean Journal Of Cancer, 1993
- PROSPECTIVE RANDOMISED TRIAL OF TAMOXIFEN VERSUS SURGERY IN ELDERLY PATIENTS WITH BREAST CANCERThe Lancet, 1988
- A HUMAN TUMOUR MODELThe Lancet, 1986
- Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine responseCancer, 1985
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST CANCER*1The Lancet, 1980
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958